新生児スクリーニングの世界市場：2023～2030年

世界の新生児スクリーニング市場は予測期間（2023～2030年）にCAGR 7.8％で成長すると予測されています。市場の成長は早期介入に起因します。早期介入は、患者の転帰を向上させるために医療においてますます不可欠になっています。最新の技術は、新生児スクリーニングという本質的な目標を達成するのに役立っています。そのため、市場各社は新たなスクリーニング装置の需要に応えるべく新製品を投入しています。例えば、2023年9月、MyLab社は新生児スクリーニングのためのMy NeoShieldという画期的なポイントオブケア新生児スクリーニング装置を発表しました。この技術は、より迅速、簡単、経済的なスクリーニングを容易にすることで、新生児医療の提供方法を変え、最終的には命を救い、病気が生涯の疾患に発展するのを防ぐことができると期待されています。世界中で新生児スクリーニングに使用されている7つの検査はすべて、この装置でサポートされています。

セグメント別の展望

聴覚スクリーニングのサブセグメントが世界の新生児スクリーニング市場でかなりのシェアを占めると予測される

検査タイプの中では、聴覚スクリーニングのサブセグメントが世界の新生児スクリーニング市場でかなりのシェアを占めると予想されます。このセグメントの成長は、新生児難聴の有病率に起因しています。新生児聴覚スクリーニングプログラムの重要性は、前述の割合によって強調されています。米国国立衛生研究所（NIH.gov）によると、2022年10月、新生児が重度または重度のPBHL（60dB[dB]超の損失）を有する場合、出生1,000人当たり1～1.5回発生します。両側性の軽度から中等度の難聴または片側性の難聴は、その程度にかかわらず、1,000人に1人から2人の割合で発生します。言語や読み書きの発達、成人としての機能、生活の質はすべて、高度および重度のPBHLによって著しく阻害されます。

地域別展望

世界の新生児スクリーニング市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他の欧州地域）、アジア太平洋（インド、中国、日本、韓国、その他アジア地域）、世界のその他の中東・アフリカ（中東およびアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。なかでも北米は、強力な市場競合企業の存在、有利な償還政策、新生児スクリーニングプログラムの利用可能性などの理由から、世界全体で顕著な市場シェアを占めると予想されます。

欧州地域は世界の新生児スクリーニング市場において著しいCAGRで成長する見込み

すべての地域の中で、欧州地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、同地域全体で診断効率が向上していることに起因しています。新生児の全ゲノムシークエンシングは、さまざまな遺伝子異常や希少疾患をも発見できる効果的な診断ツールです。早期発見と早期介入を可能にすることで、この診断精度は新生児スクリーニングの効率を大幅に向上させる。この地域で事業を展開する市場関係者と共に、政府もこのような新しい診断ツールを導入し、新生児医療サービスを向上させる取り組みをますます進めています。例えば、2022年12月、英国政府は、新生児における珍しい障害の特定における全ゲノム配列決定の効率性を検討する新たな研究であるNewborn Genomes Programmeを開始しました。血液スポット検査に加え、新生児の全ゲノム配列決定により、数千もの珍しい疾患が特定され、前述の状態で生まれた子供の生活の質が大幅に改善されました。欧州の市場関係者と政府は、さまざまなマーケティング戦略を展開することで、新生児スクリーニング市場の急速な開拓に有利な条件を整えつつあります。

さらに2021年9月、イングランド公衆衛生局（PHE）、UK National Screening Committee (UK NSC)、NHS England、NHS Improvement (NHSEI)は、イングランドにおける重症複合免疫不全症（SCID）の新生児血液スポットスクリーニングの評価を開始しました。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリスト洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• At Demant A/S
• Bio-Rad Laboratories, Inc.
• GE HealthCare Technologies Inc.
• 主要戦略分析

第4章 市場セグメンテーション

• 新生児スクリーニングの世界市場：技術別
  • タンデム質量分析
  • 液体クロマトグラフィー質量分析（LC-MS/MS）
  • パルスオキシメトリー
  • DNAマイクロアレイと次世代シーケンス（NGS）
  • 酵素ベースアッセイ
  • その他（高速液体クロマトグラフィー（HPLC）、免疫比濁法および免疫化学法）
• 新生児スクリーニングの世界市場：検査タイプ別
  • 血液スポットスクリーニング（乾燥血液スポット検査）
  • 聴覚スクリーニング（耳音響エミッションおよび聴性脳幹反応）
  • パルスオキシメトリー検査
  • 重症先天性心疾患（CCHD）
  • その他（甲状腺機能検査、汗塩化物検査、凝固検査（PT/INRおよびAPTT））
• 新生児スクリーニングの世界市場：エンドユーザー別
  • 病院および分娩センター
  • 新生児集中治療室（NICU）
  • 診断センター
  • 研究者および科学者
  • その他（医療管理者、医師・小児科医、研究所）

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 世界のその他の中東・アフリカ

第6章 企業プロファイル

• Hill-Rom Holdings, Inc.,
• India Medtronic Pvt. Ltd.
• Integrated DNA Technologies
• LifeCell International Pvt. Ltd.
• Masimo Corp.
• PerkinElmer AES
• SCIEX
• Thermo Fisher Scientific Inc.
• Trivitron Healthcare
• WATERS CORP.
• ZenTech SA

LIST OF TABLES

• 1. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL OTHERS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
• 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 10. GLOBAL NEWBORN HEARING SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 12. GLOBAL NEWBORN OTHERS SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 13. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 18. GLOBAL NEWBORN SCREENING FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 19. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 20. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 21. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 22. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
• 23. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
• 24. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 25. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 26. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
• 27. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
• 28. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 29. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 30. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
• 31. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
• 32. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 33. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 34. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
• 35. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL NEWBORN SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
• 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL OTHERS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL NEWBORN SCREENING MARKET SHARE BY TEST TYPE, 2022 VS 2030 (%)
• 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. GLOBAL NEWBORN HEARING SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 12. GLOBAL NEWBORN OTHERS SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 13. GLOBAL NEWBORN SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
• 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 18. GLOBAL NEWBORN SCREENING OTHERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 19. GLOBAL NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 20. US NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 21. CANADA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 22. UK NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 23. FRANCE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 24. GERMANY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 25. ITALY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 26. SPAIN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 27. REST OF EUROPE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 28. INDIA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 29. CHINA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 30. JAPAN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 31. SOUTH KOREA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 32. REST OF ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
• 33. REST OF THE WORLD NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)

Title: Global Newborn Screening Market Size, Share & Trends Analysis Report by Technology (Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry (LC-MS/MS), Pulse Oximetry, DNA Microarrays and Next-Generation Sequencing (NGS), Enzyme Based Assays, and Others), by Test Type (Blood Spot Screening, Hearing Screening, Pulse Oximetry Screening, Critical Congenital Heart Defect (CCHD), and Others), and by End-User (Hospitals and Birthing Centers, Neonatal Intensive Care Units (NICUs), Diagnostic Centers, Researchers and Scientists, and Others)Forecast Period (2023-2030).

The global newborn screening market is anticipated to grow at a CAGR of 7.8% during the Forecast Period (2023-2030). The market's growth is attributed to early intervention. Early intervention has become more and more essential in healthcare to enhance patient outcomes. Modern technologies help to achieve the essential goal of newborn screening. Accordingly, market players are coming up with new products to cater to the demand for new screening devices. For instance, in September 2023, MyLab introduced a revolutionary point-of-care newborn screening device named My NeoShield for newborn screening. The technology is expected to change the methods by that neonatal healthcare is provided by facilitating quicker, easier, and more economical screening, that can ultimately save lives and prevent diseases from developing into lifelong conditions. All seven tests used for newborn screening across the globe are supported by the device.

Segmental Outlook

The global newborn screening market is segmented on the technology, test type, and end-user. Based on the technology, the market is sub-segmented into tandem mass spectrometry, LC-MS/MS, pulse oximetry, DNA microarrays and NGS, enzyme based assays, and others. Based on the test type, the market is sub-segmented into blood spot screening (dried blood spot test), hearing screening (otoacoustic emissions and auditory brainstem response), pulse oximetry screening, CCHD, and others. Furthermore, based on the end-user, the market is sub-segmented into hospitals and birthing centers, NIUCs, diagnostic centers, researchers and scientists, and others. The hospitals and birthing centers subcategory is expected to capture a significant portion of the market share within the end-user segment. Rising disposable income along with a rise in patient hospitalization needs, increased prevalence of newborn diseases high-tech hospitals and healthcare infrastructure developments are additional factors propelling the market's growth.

The Hearing Screening Sub-Segment is Anticipated to Hold a Considerable Share of the Global Newborn Screening Market

Among the test types, the hearing screening sub-segment is expected to hold a considerable share of the global newborn screening market. The segmental growth is attributed to the prevalence of newborn hearing loss. The significance of newborn hearing screening programs is emphasized by the aforementioned rate. According to the National Institute of Health (NIH.gov), in October 2022, it occurs 1 to 1.5 times per 1000 live births when a neonate has severe or profound PBHL (loss of >60 dB [dB]). Bilateral mild to moderate hearing loss or unilateral hearing loss of any severity affects 1 to 2 more infants every 1000. The development of language and literacy, adult functioning, and quality of life are all significantly hindered by both severe and profound PBHL.

Regional Outlook

The global newborn screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of strong market competitors, advantageous reimbursement policies, and the availability of newborn screening programs.

The European Region is Expected to Grow at a Significant CAGR in the Global Newborn Screening Market

Among all regions, the European region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising improvement in diagnostic efficiency across the region. Newborns' whole genome sequencing is an effective diagnostic tool that can spot a variety of genetic abnormalities, even rare diseases. By enabling early detection and intervention, this degree of diagnostic accuracy can considerably improve the efficiency of newborn screening. The government along with the market players operating in the region are increasingly introducing such new diagnostic tools and initiatives to provide improved newborn healthcare services. For instance, in December 2022, the UK Government launched the Newborn Genomes Programme, a new study that examines the efficiency of whole genome sequencing in identifying uncommon disorders in newborn babies. In addition to the blood spot test, whole genome sequencing of newborns identified thousands of uncommon diseases and significantly improved the quality of life for children born with the aforementioned conditions. European market players and governments are creating favorable conditions for the rapid development of the newborn screening market by deploying different marketing strategies.

Furthermore, in September 2021, Public Health England (PHE), the UK National Screening Committee (UK NSC), NHS England, and NHS Improvement (NHSEI) launched an evaluation of newborn blood spot screening for severe combined immunodeficiency (SCID) in England.

Market Players Outlook

The major companies serving the newborn screening market include: Hill-Rom Holdings, Inc., India Medtronic Pvt. Ltd., Integrated DNA Technologies, LifeCell International Pvt. Ltd., Masimo Corp. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Eight taluk hospitals announced to launch a newborn screening. For which, the Mysuru-based All India Institute of Speech and Hearing (AIISH) collaborated with the Department of Health and Family Welfare for briefing the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening communication disorders in children. The initiative is introduced post recognizing the need for expanding the Newborn Screening Programme (NBS).

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global newborn screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. At Demant A/S,
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Bio-Rad Laboratories, Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. GE HealthCare Technologies Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Newborn Screening Market by Technology
  • 4.1.1. Tandem Mass Spectrometry
  • 4.1.2. Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
  • 4.1.3. Pulse Oximetry
  • 4.1.4. DNA Microarrays and Next-Generation Sequencing (NGS)
  • 4.1.5. Enzyme Based Assays
  • 4.1.6. Others (High-Performance Liquid Chromatography (HPLC), and Immunoturbidimetry and Immunochemistry)
• 4.2. Global Newborn Screening Market by Test Type
  • 4.2.1. Blood Spot Screening (Dried Blood Spot Test)
  • 4.2.2. Hearing Screening (Otoacoustic Emissions and Auditory Brainstem Response)
  • 4.2.3. Pulse Oximetry Screening
  • 4.2.4. Critical Congenital Heart Defect (CCHD)
  • 4.2.5. Others (Thyroid Function Testing, Sweat Chloride Test, and Coagulation Studies (PT/INR and APTT)
• 4.3. Global Newborn Screening Market by End-User
  • 4.3.1. Hospitals and Birthing Centers
  • 4.3.2. Neonatal Intensive Care Units (NICUs)
  • 4.3.3. Diagnostic Centers
  • 4.3.4. Researchers and Scientists
  • 4.3.5. Others (Healthcare Administrators, Physicians and Pediatricians, and Laboratories)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Hill-Rom Holdings, Inc.,
• 6.2. India Medtronic Pvt. Ltd.
• 6.3. Integrated DNA Technologies
• 6.4. LifeCell International Pvt. Ltd.
• 6.5. Masimo Corp.
• 6.6. PerkinElmer AES
• 6.7. SCIEX
• 6.8. Thermo Fisher Scientific Inc.,
• 6.9. Trivitron Healthcare
• 6.10. WATERS CORP.
• 6.11. ZenTech SA